tolebrutinib

Sanofi’s eyes approval after MS therapy slows disease progression by 31%
Clinical Trials Arena
Sun, 09/22/24 - 09:42 pm
Sanofi
tolebrutinib
MS
multiple sclerosis
FDA
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Fierce Biotech
Fri, 09/20/24 - 10:15 am
Sanofi
tolebrutinib
clinical trials
MS
multiple sclerosis
Sanofi finds a silver lining in mixed MS drug results
BioPharma Dive
Tue, 09/3/24 - 05:50 pm
Sanofi
tolebrutinib
MS
multiple sclerosis
clinical trials
Sanofi's mixed fortunes in MS drug trials has market focus on win
Reuters
Mon, 09/2/24 - 12:11 pm
Sanofi
multiple sclerosis
MS
clinical trials
tolebrutinib
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Wed, 06/28/23 - 11:44 am
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial
BioSpace
Fri, 02/3/23 - 10:31 am
Sanofi
tolebrutinib
myasthenia gravis
FDA Partially Halts Sanofi’s BTK Inhibitor for Multiple Sclerosis, Myasthenia Gravis
Pharma Live
Thu, 06/30/22 - 10:59 am
Sanofi
multiple sclerosis
myasthenia gravis
FDA
tolebrutinib
clinical trials
clinical hold